Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A biopharmaceutical company focused on central nervous system (CNS) diseases. Key commercial products include Qelbree (ADHD), GOCOVRI (Parkinson's), ONAPGO (Parkinson's), and ZURZUVAE (Postpartum Depression). The company operates in a single segment and recently completed the acquisition of Sage Therapeutics, Inc. in July 2025.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenues | $219,058 | $426,763 |
| Net Product Sales | $165,713 | $316,466 |
| Collaboration Revenue (ZURZUVAE) | $35,350 | $62,993 |
| Net Earnings (Loss) | $(58,371) | $(60,664) |
| Diluted EPS | $(1.01) | $(1.05) |
| Operating Cash Flow (6mo) | $61,714 | |
| Cash & Cash Equivalents (End of Period) | $179,953 | |
| Marketable Securities (End of Period) | $192,114 | |
| Total Debt | $0 (No outstanding debt on credit line) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 32% ($53.6M) for the quarter and 35% ($111.5M) for the six months compared to the prior year periods. This was driven by the inclusion of ZURZUVAE collaboration revenue (new in 2026) and strong sales of ONAPGO and Qelbree.
- Net Loss: The company reported a net loss of $58.4M for the quarter and $60.7M for the six months, compared to net earnings of $22.5M and $10.7M in the prior year periods. The shift to a loss is primarily due to a $54.9M intangible asset impairment charge related to APOKYN and increased operating expenses.
- Product Performance:
- Qelbree: Sales up 15% ($89.2M) for the quarter.
- ONAPGO: Sales up 745% ($13.5M) for the quarter following its April 2025 launch.
- APOKYN: Sales down 51% ($6.3M) for the quarter, contributing to the impairment charge.
- Trokendi XR & Oxtellar XR: Sales declined ~25% due to generic erosion.
- Expenses: Selling, general, and administrative (SG&A) expenses increased 43% for the quarter, largely due to the Biogen collaboration share and ONAPGO launch costs. R&D expenses increased 33% due to clinical program costs.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- Intangible Asset Impairment: Recognized a $54.9M non-cash impairment charge for the APOKYN intangible asset in Q2 2026 due to performance and outlook changes.
- Contingent Consideration: Paid a $33.4M milestone related to the Sage acquisition (ZURZUVAE Japan launch) in June 2026. Recorded a $2.4M loss on contingent consideration for the six months ended June 30, 2026.
- Biscayne Amendment: Paid a $10.0M milestone to former Biscayne security holders in June 2026, recorded in R&D expenses.
- Subsequent Event (Merger): On August 1, 2026, the company entered into a merger agreement with Indivior Pharmaceuticals, Inc. Supernus will become a wholly-owned subsidiary of Indivior. Supernus shareholders will receive 1.5401 shares of Indivior stock for each Supernus share. Indivior stockholders will receive a $1.0 billion special cash dividend.
- Risks & Contingencies:
- Legal Proceedings: Ongoing antitrust litigation regarding APOKYN (trial set for Jan 2027). Multiple patent infringement lawsuits filed against generic manufacturers of Qelbree (ANDA approvals stayed until Oct 2028). Securities class action and derivative litigation related to the Sage acquisition remain pending.
- Supply Chain: ONAPGO demand exceeded supply in late 2025; new patient initiation resumed in Feb 2026. A second supplier is expected in 2027 pending regulatory approval.
- Liquidity: The company maintains a $150M uncommitted credit line with no outstanding balance. Cash and marketable securities totaled $372.1M as of June 30, 2026.
Investor Verification Checklist
- Merger Terms: Verify the final exchange ratio (1.5401) and the impact of the $1.0B Indivior dividend on the combined entity's cash position.
- Impairment Rationale: Review the specific assumptions used in the discounted cash flow model for the $54.9M APOKYN impairment to assess future brand viability.
- ONAPGO Supply: Confirm the timeline for the second supplier's regulatory approval and its impact on meeting demand growth.
- Legal Exposure: Monitor the status of the APOKYN antitrust trial and the Qelbree patent litigation, as outcomes could materially affect future revenue.
- Contingent Liabilities: Track remaining milestones for the Sage acquisition (up to $201M potential) and Navitor asset purchase (up to $350M potential).